Vitreous Levels of Bevacizumab and Vascular Endothelial Growth Factor-A in Patients with Choroidal Neovascularization

Zhu, Qi; Ziemssen, Focke; Henke-Fahle, Sigrid; Tatar, Olcay; Szurman, Peter; Aisenbrey, Sabine; Schneiderhan‐Marra, Nicole; Xu, Xun; Grisanti, Salvatore

doi:10.1016/j.ophtha.2008.04.023

Cited by 152 publications

(86 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A similar report has shown slight recurrence during the follow-up period by using bevacizumab injection in patients with chronic CSC [10]. Based on the pharmacokinetics of intravitreal bevacizumab, the minimum concentration completely blocking the VEGF could be maintained for 48 days [27]. Simple injection of bevacizumab may result in limited effects because it is difficult to maintain a sufficient level of intravitreal bevacizumab.…”

Section: Discussionmentioning

confidence: 99%

Results of One-Year Follow-Up Examinations after Intravitreal Bevacizumab Administration for Chronic Central Serous Chorioretinopathy

et al. 2010

View full text Add to dashboard Cite

Background: Our purpose was to report the results of 1-year follow-up examinations after intravitreal bevacizumab injection for the treatment of chronic central serous chorioretinopathy (CSC). Methods: Five eyes in 5 patients with chronic CSC were intravitreally injected with 1.25 mg/0.05 ml of bevacizumab. The need for retreatment was evaluated if spectral-domain optical coherence tomography showed the presence of subretinal fluid at the time of a 1-month follow-up examination. Best-corrected visual acuity and central foveal thickness were compared between baseline and 1 year after the first injection. Results: The mean logarithm of the minimum angle of resolution (logMAR) best-corrected visual acuity improved from 0.23 ± 0.46 to 0.17 ± 0.47 and the mean central foveal thickness significantly decreased from 323 ± 98 µm to 171 ± 63 µm (p < 0.05). Conclusion: The intravitreal injection of bevacizumab is well tolerated in maintaining vision and reducing serous retinal detachment in patients with chronic CSC, as evaluated at a 1-year follow-up examination.

show abstract

Section: Discussionmentioning

confidence: 99%

Results of One-Year Follow-Up Examinations after Intravitreal Bevacizumab Administration for Chronic Central Serous Chorioretinopathy

et al. 2010

View full text Add to dashboard Cite

show abstract

“…64 The Tü bingen Bevacizumab Study Group investigated the vitreous levels of bevacizumab and VEGF following intravitreal injection in patients with CNV. 65 They found the pharmacokinetics of intravitreal bevacizumab to follow a two-compartment model with initial and terminal half-lives of 0.5 and 6.7 days, respectively. The peak concentration (range 2.63 ng/ml to 165 mg/ml) was observed on the second day after intravitreal bevacizumab injection; vitreous free VEGF-A levels (range 0.2-33.9 pg/ml) showed a negative correlation with bevacizumab concentration and a positive correlation with time.…”

Section: Pharmacokinetics and Pharmacodynamics In Humansmentioning

confidence: 99%

“…The peak concentration (range 2.63 ng/ml to 165 mg/ml) was observed on the second day after intravitreal bevacizumab injection; vitreous free VEGF-A levels (range 0.2-33.9 pg/ml) showed a negative correlation with bevacizumab concentration and a positive correlation with time. 65 A separate study in human non-vitrectomized eyes administered a single intravitreal injection of 1.5 mg bevacizumab reported the concentration of bevacizumab in aqueous humor to peak on the first day after injection with a mean concentration of 33.3 mg/ml (range, 16.6-42.5 mg/ml) and an aqueous half-life of 9.82 days. 66 …”

Section: Pharmacokinetics and Pharmacodynamics In Humansmentioning

confidence: 99%

Preclinical aspects of anti-VEGF agents for the treatment of wet AMD: ranibizumab and bevacizumab

Meyer

Holz

2011

Eye

110

View full text Add to dashboard Cite

Three anti-vascular endothelial growth factor (VEGF) therapies are currently used for the treatment of patients with wet age-related macular degeneration (AMD): pegaptanib, ranibizumab, and bevacizumab. Ranibizumab is an antibody fragment approved for the treatment of wet AMD. Bevacizumab is a fulllength antibody registered for use in oncology but unlicensed for wet AMD. However, it is used off-label worldwide not only for wet AMD but also for various other ocular diseases associated with macular edema and abnormal vessel growth. We consider aspects of ranibizumab and bevacizumab in relation to their molecular characteristics, in vitro and in vivo properties, and preclinical safety data. Before 2009, most studies described the shortterm toxicity of bevacizumab in multiple cell types of the eye. Since 2009, an increasing number of studies have compared the properties of ranibizumab and bevacizumab and investigated their impact on retinal cell functioning. Compared with bevacizumab, ranibizumab neutralizes VEGF better at low concentrations, maintains efficacy for longer, and has a higher retinal penetration and potency. Studies in animals demonstrate ranibizumab to be better localized to the injected eye, whereas bevacizumab appears to have a greater effect in the fellow eye. In humans, a localized and systemic effect has been reported for both molecules. In conclusion, overlapping yet distinct pharmacological properties of ranibizumab and bevacizumab indicate that safety or efficacy data from one cannot be extrapolated to the other.

show abstract

“…Studies suggest an initial vast excess of VEGF-binding activity after intravitreal injections of both bevacizumab and ranibizumab (Zhu et al 2008;Funk et al 2009). Assuming treatment resistance is caused by a VEGF-driven mechanism, one can hypothesize that it is towards the end of the monthly interval that the level of VEGF in the eyes exceeds the amount of anti-VEGFbinding activity.…”

mentioning

confidence: 99%

Initial improvements when converting eyes with treatment‐resistant exudative AMD to aflibercept are substantially diminished after increasing treatment intervals from 4 to 8 weeks

Jørstad

Faber

Moe

2015

Acta Ophthalmologica

View full text Add to dashboard Cite

Vitreous Levels of Bevacizumab and Vascular Endothelial Growth Factor-A in Patients with Choroidal Neovascularization

Cited by 152 publications

References 22 publications

Results of One-Year Follow-Up Examinations after Intravitreal Bevacizumab Administration for Chronic Central Serous Chorioretinopathy

Results of One-Year Follow-Up Examinations after Intravitreal Bevacizumab Administration for Chronic Central Serous Chorioretinopathy

Preclinical aspects of anti-VEGF agents for the treatment of wet AMD: ranibizumab and bevacizumab

Initial improvements when converting eyes with treatment‐resistant exudative AMD to aflibercept are substantially diminished after increasing treatment intervals from 4 to 8 weeks

Contact Info

Product

Resources

About